RACA Therapeutics Acquisition Corp. - Class A

Therapeutics Acquisition Corp. is a blank check company with a purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Peter Kolchinsky and Matthew Hammond on April 15, 2020 and is headquartered in Boston, MA.

On 3/15/2021 the company announced a pending merger with POINT Biopharma, a late-stage biopharmaceutical company dedicated to bringing the many benefits of precision radiopharmaceutical therapies to patients with cancer. Assuming no redemptions, the SPAC shareholders will own 19% of the company. The $165 million PIPE at $10 per share will own 18%. Valuation is difficult to measure as POINT has no revenues.  

As of 06/21/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Financials
Industry:  Shell Companies
Index country:  USA
Country of incorporation:  
IPO date:  08/07/2020
Outstanding shares:  14,041,400
Average volume:  20,705
Market cap:   $142,520,210
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy